GlassScriptPhysician profile
Sue Lee Kim
NPI 1669130142
$2,405.11
in general payments reported to CMS, 2019-2025
39 companies · $985 in 2025
The $985 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $253 · 2023: $421 · 2024: $746 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123 · Education: $29.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.75 |
| Education | $29.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $417.10 | 2022-2025 | Lynparza, Calquence, Enhertu |
| Pfizer INC. | $220.85 | 2024-2025 | |
| Astellas Pharma US INC | $190.01 | 2023-2025 | Veozah, Vyloy, Xospata |
| Glaxosmithkline, LLC. | $157.28 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Seagen INC. | $130.32 | 2023 | Tivdak |
| Amgen INC. | $124.74 | 2025 | Evenity |
| Merck Sharp & Dohme LLC | $122.73 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $111.07 | 2024-2025 | Rybrevant, Talvey, Darzalex |
| Celgene Corporation | $106.98 | 2024-2025 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $80.27 | 2024-2025 | |
| Sobi, INC | $60.46 | 2025 | |
| Abbvie INC. | $51.68 | 2024 | |
| Coherus Oncology, INC. | $45.72 | 2024-2025 | Loqtorzi |
| Blueprint Medicines Corporation | $37.46 | 2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $30.75 | 2024 | Iclusig |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $29.97 | 2024 | |
| Tempus Ai, INC | $28.02 | 2025 | Xt Cdx |
| Aveo Pharmaceuticals, INC. | $26.46 | 2025 | |
| Solventum Corporation | $26.31 | 2025 | Prevena |
| Immunogen, INC. | $24.31 | 2023 | Elahere |
| Beone Medicines USA, INC. | $24.30 | 2025 | Brukinsa |
| Beigene USA, INC. | $24.10 | 2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $23.16 | 2025 | |
| Dendreon Pharmaceuticals LLC | $22.84 | 2024 | Provenge |
| Exelixis INC. | $22.57 | 2024 | Cabometyx |
| Davol INC. | $22.56 | 2024 | Arista Ah Flexitip |
| Daiichi Sankyo INC. | $20.85 | 2025 | Enhertu |
| Stemline Therapeutics INC. | $20.82 | 2024 | Orserdu |
| Legend Biotech USA INC. | $20.49 | 2025 | Carvykti |
| Karyopharm Therapeutics INC. | $20.44 | 2024 | Xpovio |
| Lilly USA, LLC | $19.90 | 2025 | Retevmo, Verzenio, Jaypirca |
| Vbi Vaccine (Delaware) INC. | $19.78 | 2023 | Prehevbrio |
| Genentech USA, INC. | $19.62 | 2024 | Tecentriq, Polivy, Alecensa |
| Incyte Corporation | $19.20 | 2024 | Jakafi |
| Adc Therapeutics America, INC. | $18.48 | 2025 | |
| Gilead Sciences, INC. | $16.46 | 2024 | |
| Myriad Genetic Laboratories, INC. | $16.46 | 2022 | |
| Array Biopharma INC | $15.79 | 2025 | Mektovi, Tukysa, Braftovi |
| Shield Therapeutics INC | $14.80 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sue Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.